ArticleJournal of arrhythmia2026
Predictors and Outcomes of 30-Day Readmissions Following Electrical Cardioversion for Atrial Fibrillation: Insights From the Nationwide Readmissions Database.
Article in Journal of arrhythmia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atrial Fibrillation (AF) affects 10.5 million adults in the US and is projected to reach 12.1 million by 2030, representing a growing burden. We evaluated predictors of 30-day readmission after electrical cardioversion (EC) for AF. Methods: In this retrospective observational cohort study using the Nationwide Readmissions Database (2016-2017), we identified adults with AF undergoing EC. Outcomes evaluated were 30-day all-cause readmission, in-hospital mortality, length of stay (LOS) and inflation-adjusted hospitalization charges. Multivariable logistic regression identified predictors of 30-day readmission. Results: Among 134 114 AF hospitalizations managed with EC, 13 260 (9.9%) were readmitted within 30 days. Readmitted patients (mean age 70, 51% male) had longer index stays (4 vs. 3 days), higher charges ($31 576 vs. $26 896), and more frequent nonhome discharges (11% vs. 6.4%; all Conclusion: Nearly 1 in 10 AF patients treated with EC was readmitted within 30 days. Female sex, comorbidity burden and lower socioeconomic status were key predictors. Improved post-discharge care addressing comorbidities alongside rhythm management may reduce early readmissions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.